Gilead Sciences (GILD) EBITDA Margin (2009 - 2026)
Gilead Sciences' (GILD) quarterly EBITDA Margin came in at 133.21% in Q2 2026, down 16814.0% on a YoY basis from N/an in Q2 2025, and down 458.51% quarter-over-quarter from 37.16% in Q1 2026.
Powered by 
Analysis
Gilead Sciences (GILD) EBITDA Margin (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported EBITDA Margin for 18 consecutive years, with 133.21% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin fell 16814.0% year-over-year to 133.21%; the trailing twelve-month figure through Jun 2026 stood at 8.2% (down 3609.0% YoY), and the FY2025 full-year result was 34.04%, up 2826.0% from the prior year.
- EBITDA Margin retreated to 133.21% in Q2 2026 per GILD's latest filing, from 37.16% in the prior quarter.
- Across five years, EBITDA Margin topped out at 42.82% in Q3 2025 and bottomed at 133.21% in Q2 2026.
- Historically, EBITDA Margin has averaged 15.34% across 5 years, with a median of 31.54% in 2024.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin jumped 9820 bps in 2025, then sank 16814 bps in 2026.
- Over 5 years, EBITDA Margin stood at 30.68% in 2022, then dropped by 26 bps to 22.66% in 2023, then jumped by 43 bps to 32.4% in 2024, then fell by 23 bps to 25.03% in 2025, then tumbled by 632 bps to 133.21% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 133.21%, 37.16%, and 25.03% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.09 Bn | 193.10 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.68 Bn | 176.50 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.79 Bn | 73.79 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.15 Bn | 55.97 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.35 Bn | 48.21 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.40 Bn | 30.10 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.66 Bn | 30.38 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.14 Bn | 29.14 Bn | 1.16 Mn | -25,380.93% |
| 10 | Insmed | 27.69 Bn | 26.53 Bn | 358.27 Mn | -0.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -133.21% |
| Mar 31, 2026 | 37.16% |
| Dec 31, 2025 | 25.03% |
| Sep 30, 2025 | 42.82% |
| Jun 30, 2025 | 34.93% |
| Mar 31, 2025 | 33.55% |
| Dec 31, 2024 | 32.40% |
| Sep 30, 2024 | 11.77% |
| Jun 30, 2024 | 38.02% |
| Mar 31, 2024 | -64.64% |
| Dec 31, 2023 | 22.66% |
| Sep 30, 2023 | 37.20% |
| Jun 30, 2023 | 25.23% |
| Mar 31, 2023 | 26.84% |
| Dec 31, 2022 | 30.68% |
| Sep 30, 2022 | 40.29% |
| Jun 30, 2022 | 32.41% |
| Mar 31, 2022 | 2.99% |
| Dec 31, 2021 | 12.98% |
| Sep 30, 2021 | 51.77% |